ArticleScientific reports2025
Patterns and prognostic implications of distant metastasis in breast Cancer based on SEER population data.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Oral selective estrogen receptor degraders in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis.Breast cancer research and treatment · 2026Pooled it
- Liquid biopsy reveals the immune status and protein profiles linked to CTC burden and clinical outcomes in metastatic breast cancer.Journal of experimental & clinical cancer research : CR · 2026Trial
- Gastric and peritoneal metastases from breast carcinoma with a mixed ductal-lobular phenotype and aberrant E-cadherin: a case report.Journal of surgical case reports · 2026Article
- A Novel Advanced Breast Cancer Risk Stratification Model Represents an Opportunity to Identify High-Risk Women for Increased Screening.Journal of general internal medicine · 2026Article
- Loss of TIMM8A Inhibits Breast Cancer Progression Through Promoting HSPA9 Ubiquitination and Degradation via Competitive Interaction with RNF4.International journal of molecular sciences · 2026Article
- Timing and Patterns of Relapse-Related Events Following Adjuvant CDK4/6 Inhibitors Combined With Endocrine Therapy in Patients With HR-Positive, HER2-Negative Early Breast Cancer.Cancer medicine · 2026Article
- External validation of a nomogram for de novo bone metastasis in breast cancer: a single-center Mexican cohort.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Article
- Loss of Arginase 2 Promotes Lung Metastasis in immune-competent hosts via Nitric Oxide Synthase 2-Dependent Th17 Response.bioRxiv : the preprint server for biology · 2026Article
- Practice disparities in palliative radiation therapy for bone metastases: insights from the Shizuoka Kokuho database study.Japanese journal of radiology · 2026Article
- Molecular subtype concordance and metastatic patterns in muscle-invasive bladder cancer.The journal of pathology. Clinical research · 2026Article
- Review
- Review
- Glucocorticoid-Induced Proteome and Phosphoproteome Changes in Breast Cancer Cell Lines.Journal of proteome research · 2026Article
- Differences in distant metastasis risk of breast cancer originating from various primary sites: a retrospective analysis based on the SEER database.Scientific reports · 2026Article
- From Feasibility to Individualization: Surgery for Breast Cancer Liver and Lung Metastases.Cancers · 2026Review
- Artificial Intelligence in Triple-Negative Breast Cancer: Applications in Diagnosis, Treatment Response, and Prognosis.Diagnostics (Basel, Switzerland) · 2026Review
- [Force-regulation mechanism of E-selectin mediated adhesion and activation of MDA-MB-231 cells under fluid shear stress].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2026Article
- Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane.NPJ breast cancer · 2026Article
- Organ-Specific Clinicopathological Features That Are Associated With Post-Relapse Survival of Metastatic Breast Cancer in Japanese Women: A Multicenter Cohort Study.World journal of oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Distant metastasis remains the leading cause of mortality in breast cancer, yet comprehensive population-based evaluations of metastatic site combinations and their survival implications are limited. This study aimed to explore the clinicopathological determinants and prognostic outcomes of site-specific and multi-organ metastases in breast cancer using SEER data. A total of 200,558 female breast cancer patients diagnosed between 2014 and 2023 were extracted from the SEER database. Logistic regression was used to assess associations between clinicopathological features and metastatic patterns. Kaplan-Meier analysis and Cox proportional hazards models were applied to evaluate overall survival (OS) across different metastatic site combinations. Among patients with distant metastasis classified into 15 common metastatic patterns, bone was the most common metastatic site (21.3%), followed by lung (16.1%), liver (9.2%), and brain (2.9%). Molecular subtypes showed distinct organotropism: HR+/HER2 - tumors were prone to bone-only metastasis, whereas HER2-positive and triple-negative subtypes were more likely to involve visceral and brain metastases. Multi-organ metastases, especially combinations including the brain (e.g., brain + liver + lung), were associated with the poorest prognosis (median OS: 4.0 months). Younger age (≤ 40 years), higher histological grade (Grade III), and tumor location in the axillary tail or unspecified regions were independently associated with increased metastatic risk. Grade III tumors exhibited broader visceral spread and significantly worse survival compared to lower-grade tumors. This is the first population-based study to systematically characterize 15 metastatic site combinations and their survival outcomes across molecular subtypes. The findings highlight the heterogeneity of breast cancer metastasis and underscore the need for subtype-specific, site-targeted surveillance strategies and prognostic assessment tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.